Valuation dispersion widened again this week as capital continued rotating unevenly across healthcare, insurance, consumer staples, travel, and business services. While price action has remained largely driven by macro headlines and positioning shifts, a separate signal emerged beneath the surface: several companies are still trading at substantial discounts to their modeled cash-flow value despite operating in very different parts of the market.
Using the DCF Valuation API, this week's screen surfaced five companies where the gap between modeled intrinsic value and current market pricing remains unusually wide. In this report, we'll examine those names, explore what the valuation spreads may be signaling across sectors, and walk through the API workflow used to identify and monitor these opportunities over time.
Key Takeaways
- This week's DCF screen identified five companies across healthcare and insurance where modeled intrinsic value remained substantially above current market pricing, highlighting valuation dispersion across unrelated sectors.
- The appearance of BDX, ZBH, AIG, TRV, and UHS in the same screen suggests the signal is not tied to a single industry narrative, but may reflect broader differences between market sentiment and long-term cash-flow assumptions.
- Valuation gaps become more meaningful when analyzed alongside supporting datasets such as earnings trends, analyst estimate revisions, balance-sheet strength, and free cash flow generation rather than in isolation.
Five Companies Standing Out in This Week's Valuation Screen
Becton, Dickinson and Company (BDX)
DCF Value: $1,159.56 — Market Price: $143.92 → Upside Potential: +705.7%
Among this week's results, Becton Dickinson produced the widest valuation spread in the screen. The company sits at the intersection of several healthcare categories, including medical devices, diagnostics, medication delivery systems, and hospital infrastructure, which often makes its earnings profile less cyclical than many healthcare peers. A DCF value substantially above the current market price does not necessarily imply mispricing, but it does indicate that the assumptions embedded within the model differ materially from the assumptions currently reflected in the market.
That divergence becomes more interesting when viewed alongside the company's ongoing transformation. Earlier this year, BD lowered its profit outlook following the separation of its Biosciences and Diagnostic Solutions business, while continuing to navigate pricing pressure in China and slower upgrade cycles for certain product lines. At the same time, management reported revenue and earnings results that exceeded analyst expectations, highlighting the complexity of the transition currently underway.
For analysts evaluating whether the valuation gap reflects operating fundamentals or market skepticism, the most useful datasets would likely be segment-level income statement trends, margin performance, and management guidance revisions. Those inputs provide context around whether cash-flow expectations are diverging because of temporary restructuring effects or longer-duration changes in profitability.
Zimmer Biomet Holdings, Inc. (ZBH)
DCF Value: $477.56 — Market Price: $88.27 → Upside Potential: +440.8%
Zimmer Biomet stands out as another healthcare name generating an unusually large spread between modeled value and current pricing. The orthopedic-device manufacturer operates in a market supported by long-term demographic trends, yet its valuation continues to reflect a degree of caution. That contrast is precisely the type of setup this screen is designed to identify—not because it predicts an outcome, but because it highlights where market pricing and modeled cash-flow expectations appear to be telling different stories.
Recent developments help explain why the signal may exist. The company has been working through a multi-year overhaul of its U.S. sales organization while simultaneously investing in robotic surgery and digital orthopedic platforms. Recent earnings exceeded expectations and management raised its profit forecast, but investors also focused on execution challenges tied to the commercial transition and a relatively cautious revenue outlook.
In this case, tracking analyst estimate revisions, procedure-volume trends, and segment revenue growth may offer more insight than headline valuation metrics alone. The key question is not whether the valuation gap closes, but whether operating performance and market expectations begin moving closer together over time.
American International Group, Inc. (AIG)
DCF Value: $370.69 — Market Price: $74.01 → Upside Potential: +400.9%
AIG's appearance on the screen highlights an important feature of valuation analysis: large spreads are not confined to growth-oriented sectors. Insurance businesses often generate stable cash flows, but they are also highly sensitive to assumptions surrounding underwriting profitability, reserve development, investment income, and capital allocation. Small changes in those variables can create significant differences between market value and modeled intrinsic value.
Unlike healthcare companies, where innovation cycles often dominate the discussion, the insurance story is frequently about discipline and consistency. For AIG, investors have spent several years assessing the company's operational simplification efforts, underwriting performance, and return-on-equity profile following a broader restructuring period. When a valuation model produces a spread of this magnitude, it suggests that one or more of those underlying assumptions deserve closer examination.
The most informative datasets here would be combined ratio trends, investment portfolio performance, capital return activity, and analyst target revisions. Together, they provide a clearer picture of whether the valuation gap is being driven by earnings power, balance-sheet assumptions, or broader sentiment toward the insurance sector.
The Travelers Companies, Inc. (TRV)
DCF Value: $1,001.82 — Market Price: $307.81 → Upside Potential: +225.5%
Travelers generated a smaller spread than some of the other companies in this screen, but it remains substantial relative to its current market value. Unlike many valuation screens that become concentrated in a single industry, Travelers demonstrates that disconnects can emerge even within mature, well-covered businesses where information availability is rarely a limiting factor.
The property-and-casualty insurance industry has spent the last several years balancing higher premium rates against elevated catastrophe losses and inflation-driven claims costs. As a result, investors often focus heavily on underwriting quality, reserve adequacy, and catastrophe exposure when evaluating insurers. A valuation spread of this size suggests the market may be placing more weight on near-term uncertainties than the cash-flow assumptions embedded in the model.
For readers monitoring the signal, quarterly underwriting metrics, catastrophe-loss disclosures, and investment-income trends are likely to be more informative than share-price movements alone. These datasets tend to reveal whether valuation differences are rooted in temporary industry conditions or more persistent changes in profitability.
Universal Health Services, Inc. (UHS)
DCF Value: $375.26 — Market Price: $141.52 → Upside Potential: +165.2%
Universal Health Services rounds out this week's list and introduces a different healthcare dynamic than BDX or ZBH. As one of the largest hospital and behavioral-health operators in the United States, UHS is influenced less by product cycles and more by patient volumes, reimbursement trends, labor costs, and facility utilization rates. Those variables often create a different valuation profile from traditional medical-device companies.
The company's presence in the screen is notable because healthcare operators have spent recent years navigating staffing pressures, wage inflation, and changing reimbursement environments. While many of those challenges have become familiar to investors, the valuation spread suggests that the assumptions driving long-term cash-flow expectations remain materially different from those reflected in current market pricing.
Hospital admission trends, occupancy metrics, reimbursement data, and operating-margin performance would likely provide the clearest framework for interpreting the signal. When valuation models and market prices diverge in provider businesses, those operational indicators often help explain whether the gap stems from profitability assumptions, utilization expectations, or broader sector sentiment.
Reading a Common Signal Across Unrelated Sectors
What makes this week's screen notable is not the size of the valuation gaps themselves, but where they appeared. The five companies span medical devices, hospital operations, and property & casualty insurance: industries with different economic drivers, regulatory environments, and investor bases. Yet despite those differences, each produced the same underlying signal: modeled cash-flow value remained materially above current market pricing.
That pattern suggests the screen is detecting something broader than a sector-specific narrative. In environments where macro uncertainty, earnings revisions, and capital rotation dominate positioning decisions, valuation compression often emerges unevenly across the market. Investors may reduce exposure to entirely different industries for entirely different reasons, but the result can look surprisingly similar at the valuation level: market prices become more conservative than the assumptions embedded in long-term cash-flow models. Whether that reflects legitimate fundamental concerns or temporary sentiment shifts is a separate question, but the clustering itself is worth monitoring.
Importantly, a DCF screen is most useful when treated as the starting point of an investigation rather than the conclusion. Once a valuation gap appears, the next step is determining whether the underlying fundamentals support the signal. For example, comparing DCF outputs against operating trends from the Income Statement API can help reveal whether revenue growth, margins, and earnings trajectories are moving in the same direction as the valuation model. Looking at balance-sheet data adds another layer, particularly for insurers and capital-intensive healthcare businesses where leverage, reserves, or liquidity can materially influence intrinsic value assumptions.
Additional context can come from consensus expectations. If analyst targets remain clustered near current prices while DCF estimates diverge sharply, the signal may point to a difference in assumptions rather than an overlooked opportunity. Conversely, when valuation spreads appear alongside improving analyst revisions, stronger earnings trends, or expanding free cash flow, the data begins telling a more cohesive story. That is where a broader dataset becomes useful: combining DCF outputs with analyst estimates, price targets, rating histories, and financial statement data available through FMP can help determine whether a valuation gap is supported by multiple independent signals or exists primarily within a single model framework.
Viewed through that lens, this week's screen is less about five individual companies and more about a recurring research process. The most useful observation is not that healthcare or insurance appeared on the list—it is that multiple businesses with very different operating models generated the same valuation signal at the same time. That kind of cross-sector alignment often provides a stronger reason to investigate further than any single company appearing in isolation.
Turning DCF Snapshots Into a Live, Repeatable Signal
A single DCF output can highlight a pricing gap, but on its own it's just a snapshot. Market prices update continuously, while model inputs—growth rates, margins, discount assumptions—shift as new data comes in. To make the signal usable, the focus needs to move from one-off checks to consistent data capture. That means running the same extraction on a schedule, storing each pull, and observing how valuation spreads change over time rather than treating them as isolated readings.
Before starting the workflow, confirm that your API key is properly configured and accessible in your environment.
Step 1. Query the DCF Valuation API
The workflow starts with the DCF Valuation API, which serves as the foundation for the entire process. This endpoint returns both the modeled intrinsic value and the current market price in one response, removing the need to reconcile multiple data sources before analysis begins. Having valuation and price captured together ensures consistency and reduces the risk of timing mismatches that can distort comparisons.
Sample response
|
[ { "symbol": "AAPL", "date": "2025-02-04", "dcf": 147.27, "Stock Price": 231.80 } ] |
Step 2. Compute the Upside
With both fields in hand, the next step is to normalize the gap. Converting the difference between DCF and market price into a percentage allows the results to be compared across names with very different share prices:
Upside % = (DCF - Stock Price) / Stock Price × 100
In the example above, the calculation produces roughly -36%, indicating the stock is trading above the modeled intrinsic value. Positive figures flag the opposite condition—where price sits below DCF—which is the core signal this screen is designed to capture.
Step 3. Scale It into a Screening Loop
The workflow becomes materially more useful once this logic is applied at scale. Running the DCF endpoint across a defined universe, calculating the percentage spread for each symbol, storing the results, and ranking them by upside converts a static check into a living screen. When automated on a recurring cadence, the process continuously surfaces where price and intrinsic value are drifting further apart or beginning to converge, making it easier to monitor valuation pressure as market conditions shift.
Stabilizing the Workflow Before Scaling It
Before expanding a valuation screen across hundreds or thousands of symbols, the more important question is whether the process behaves consistently under repeat conditions. Early-stage testing is less about market coverage and more about validation: confirming that DCF outputs reconcile properly, percentage spreads calculate cleanly, and rankings update logically as new data enters the system. For that stage, the FMP Basic plan is generally enough to establish whether the workflow itself is dependable.
Once the mechanics are stable, scaling becomes an infrastructure decision rather than a methodological one. The same extraction logic, normalization process, and ranking framework can simply be applied across a broader universe using the FMP Starter plan, which adds wider market coverage and deeper historical access. The signal itself does not change — only the breadth of the environment it runs against. That consistency matters because it keeps comparisons aligned as the dataset expands.
For workflows operating on tighter refresh cycles or across international markets, throughput starts to matter more than screen construction. The FMP Premium plan supports that transition with higher request capacity and broader exchange access, making it easier to run the process continuously around earnings releases, estimate revisions, or macro-driven volatility windows. At that stage, the screen stops functioning like a periodic valuation check and starts behaving more like part of the ongoing research infrastructure.
When a Valuation Workflow Becomes Research Infrastructure
Signals that consistently hold up under market pressure rarely remain confined to a single analyst workflow. Once a valuation framework starts influencing sector reviews, allocation discussions, or risk meetings, the limitations of fragmented implementations become more visible. Teams may be using the same conceptual model, but differences in ticker universes, update frequency, normalization logic, or historical storage quickly create inconsistencies that undermine comparability across desks.
In practice, the analysts closest to the workflow often become the internal drivers of standardization. After refining the screen through repeated market cycles, the priority shifts away from experimentation and toward consistency: locking calculation logic, aligning data inputs, and ensuring that everyone evaluating the signal is working from the same underlying assumptions. That transition matters because valuation frameworks become materially more useful once they can be referenced across teams without requiring reconciliation between separate spreadsheets or independently maintained scripts.
As adoption expands across research groups, portfolio teams, or regional desks, the infrastructure surrounding the workflow becomes as important as the screen itself. Shared dashboards reduce duplication, centralized storage preserves historical outputs for auditability, and permission controls help prevent silent methodology drift over time. The objective is not simply operational efficiency — it is analytical coherence. When multiple teams are discussing valuation dispersion, factor exposure, or earnings sensitivity, confidence in the conversation depends on confidence in the underlying data framework being synchronized across the organization.
That is typically the point where desk-level tooling evolves into institutional research infrastructure. Frameworks that began as analyst-built screens often migrate toward more formal environments designed for controlled access, consistent delivery, and governance across broader user groups. An institutional setup such as the FMP Enterprise Plan becomes relevant less as a scaling upgrade and more as a way to preserve methodological integrity as usage broadens across teams, strategies, and regions.
Using Valuation Gaps to Frame What Comes Next
This week's screen highlights how valuation disconnects can emerge across very different industries at the same time, often revealing questions that market pricing and cash-flow models are answering differently. The value of the DCF Valuation API is not in providing a conclusion, but in creating a repeatable framework for identifying those divergences and tracking whether the underlying data begins to reinforce or challenge them over time.
Expand your watchlist with our previous deep dive: Signals Desk Weekly Take via FMP API | Five Companies With Persistent Earnings Beats (June 8-12)
Disclosure: Signals Desk content is provided for informational and analytical purposes only and does not constitute investment advice or trade recommendations. The analysis reflects interpretation of market data and publicly disclosed or third-party information, including data accessed via Financial Modeling Prep APIs, at the time of publication. Signals discussed are probabilistic, can be wrong, and may change as market conditions and consensus data evolve. This content should be considered alongside broader research, individual objectives, and risk assessment.
